The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

Patrizia Chiusolo, Nicola Piccirillo, Luca Laurenti, Stefan Hohaus, Simona Sica, Sabrina Giammarco, Silvia Bellesi, Elisabetta Metafuni, Daniela Giovanna De Ritis, Sara Marietti, Luana Fianchi, Giuseppe Leone, S Federica

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

In the last years, the influence of different genes involved in metabolism of chemotherapeutic agents has been studied. Methotrexate (MTX) is a key compound of chemotherapeutic regimens used in the treatment of acute lymphoblastic leukemia (ALL), primary central nervous system lymphoma (PCNSL) and Burkitt's lymphomas (BL). This study aims to evaluate the role of MTHFR C677T and A1298C polymorphisms and G80A reduced folate carrier gene (RFC1) in a cohort of adult patients with lymphoproliferative malignancies submitted to high-dose MTX followed by leucovorin rescue.
Original languageEnglish
Pages (from-to)691-696
Number of pages6
JournalCancer Chemotherapy and Pharmacology
Volume69
DOIs
Publication statusPublished - 2012

Keywords

  • Adolescent
  • Adult
  • Aged
  • Animals
  • Antineoplastic Combined Chemotherapy Protocols
  • Cohort Studies
  • Disease-Free Survival
  • Hematologic Neoplasms
  • Humans
  • Kaplan-Meier Estimate
  • Leucovorin
  • Male
  • Methotrexate
  • Methylenetetrahydrofolate Reductase (NADPH2)
  • Middle Aged
  • Polymorphism, Genetic
  • Reduced Folate Carrier Protein
  • Young Adult

Fingerprint

Dive into the research topics of 'The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue'. Together they form a unique fingerprint.

Cite this